What Is Dactinomycin Used For? Approved Uses, Per the Label

Dactinomycin is a prescription medicine approved by the US Food and Drug Administration, supplied as a sterile powder for injection and known in the older literature as actinomycin D. It is marketed in the United States under the brand name Cosmegen, and generic dactinomycin for injection products are also approved. This page summarises the indications that appear in the approved US prescribing information, the published trial literature associated with those indications, and how the labelled wording came to look the way it does. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning diagnosis, treatment or whether a particular medicine is appropriate. No dosing information appears here.

The approved indications, as the label frames them

The current US prescribing information for dactinomycin for injection groups the approved uses into three blocks. The first covers four tumour types treated with dactinomycin as part of a combination chemotherapy regimen or a multimodality treatment regimen that may also include surgery and radiation. The second covers gestational trophoblastic neoplasia, where the label permits use either as a single agent or within a combination regimen. The third covers regional perfusion, a specialised surgical delivery technique used for disease confined to a limb or region.

The revision date of the labelling appears on the FDA-approved prescribing information itself, and the exact wording of each indication should be read from that document rather than from any summary. A separate background page on this site covers the compound itself at PeptideU: dactinomycin.

Indication by indication: the published evidence

Wilms tumour

Dactinomycin has been part of paediatric Wilms tumour regimens since the earliest cooperative group protocols, usually alongside vincristine and, in higher risk disease, doxorubicin, with surgery and sometimes radiation. A 2005 review of Wilms tumour management described how sequential cooperative group studies refined chemotherapy selection and staging so that treatment intensity could be matched to risk group (PMID 15928519). That review is a useful entry point for readers who want to understand why a decades-old antibiotic remains embedded in modern multimodality protocols for this tumour (PMID 15928519).

Rhabdomyosarcoma

The label lists rhabdomyosarcoma as a combination chemotherapy indication, reflecting the long-standing vincristine, dactinomycin and cyclophosphamide backbone used in paediatric soft tissue sarcoma protocols. Laboratory work continues alongside clinical practice: a 2023 report described rhabdomyosarcoma xenotransplants in zebrafish embryos as a model system for studying tumour behaviour and drug response (PMID 36317680). That work was preclinical and did not form part of the approval basis for the indication (PMID 36317680).

Ewing sarcoma and metastatic nonseminomatous testicular cancer

Both of these appear in the same labelled sentence as Wilms tumour and rhabdomyosarcoma, again as part of combination chemotherapy or multimodality treatment. In both settings dactinomycin is one component of a regimen rather than a stand-alone therapy, and the choice of regimen is made by the treating oncology team. Whether dactinomycin features in a given plan depends on the protocol, the stage of disease and the individual clinical picture, which is a conversation for a prescribing clinician.

Gestational trophoblastic neoplasia

Gestational trophoblastic neoplasia is the one labelled setting in which dactinomycin may be used as a single agent. A 2002 review of gestational trophoblastic disease outlined the diagnostic framework, risk scoring and the role of chemotherapy in low-risk and high-risk disease (PMID 12196865).

For low-risk disease, a multicentre randomised clinical trial published in 2022 compared chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin against multi-course methotrexate (PMID 34181195). The study was designed to test whether a shorter, intensified start changed outcomes relative to the conventional repeated-course approach, and researchers reported the comparison across participating centres (PMID 34181195).

For high-risk disease, a 2021 analysis compared the M-EA regimen, built from methotrexate, etoposide and dactinomycin, with the EMA-CO regimen, which adds cyclophosphamide and vincristine, as first-line treatment (PMID 33210289). Both regimens contain dactinomycin, which illustrates how the labelled combination wording maps onto real-world protocols (PMID 33210289).

Chemotherapy is not the only management option studied in this disease. A 2018 report examined first-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia who no longer wished to conceive (PMID 29887485). That work is relevant context because it shows that the role of a drug such as dactinomycin is weighed against surgical alternatives and fertility preferences by the treating team (PMID 29887485).

Regional perfusion

The label also covers dactinomycin as a component of regional perfusion for locally recurrent or locoregional solid malignancies. Regional perfusion isolates the circulation of a limb or region so that chemotherapy can be delivered locally. This is a hospital procedure performed by surgical and oncology specialists, and the labelled indication reflects that setting rather than routine systemic administration.

How the labelled indications developed

Dactinomycin belongs to the actinomycin family of cytotoxic antibiotics isolated from Streptomyces species, and it has been in US clinical use since the 1960s, making it one of the oldest anticancer medicines still in routine practice. A reference chapter on cytotoxic antibiotics describes the shared pharmacology of this class, including the way these agents intercalate into DNA and interfere with transcription (PMID 31643644).

Because the original approval predates the modern format of US labelling, the indication wording has been updated over time to align with current standards, including language that frames the drug as part of a combination or multimodality regimen rather than as a general purpose cytotoxic. The tumour types listed have remained anchored in paediatric solid tumours, testicular cancer and gestational trophoblastic neoplasia, the settings where cooperative group protocols and trials of regimens containing dactinomycin accumulated the most evidence (PMID 15928519, PMID 33210289).

Mechanistic work has continued in parallel. A 2021 report linked dactinomycin activity to a nucleolar stress response in relapsed or refractory NPM1-mutated acute myeloid leukaemia, where complete remission was observed (PMID 33654209). That mechanism, inhibition of ribosomal RNA synthesis in the nucleolus, is consistent with the class description of cytotoxic antibiotics (PMID 31643644).

Safety and tolerability: What Studies Report

The approved labelling carries boxed and other warnings that a prescribing clinician reviews before treatment, including warnings relating to extravasation injury, hepatic toxicity such as veno-occlusive disease, myelosuppression and secondary malignancy risk when combined with radiation. In the published literature, the reference chapter on cytotoxic antibiotics places dactinomycin within a class whose toxicity profile is well characterised and monitored, including liver-related effects (PMID 31643644).

Comparative trials in gestational trophoblastic neoplasia were structured in part around tolerability. The randomised trial of chemotherapy initiation in low-risk disease compared methotrexate alone with methotrexate plus dactinomycin and with multi-course methotrexate, so that efficacy and treatment burden could be weighed together (PMID 34181195). The comparison of M-EA and EMA-CO in high-risk disease similarly examined two multi-agent regimens that differ in the number of cytotoxic drugs administered (PMID 33210289). Readers who want the full adverse reaction table should read the approved prescribing information and discuss it with a clinician rather than relying on summaries.

A short note on uses that are not approved

Several published reports describe dactinomycin in settings that are not approved indications and are presented here only as research context, not as uses. These include the report of complete remission in relapsed or refractory NPM1-mutated acute myeloid leukaemia (PMID 33654209), laboratory work on synergy between photodynamic therapy and dactinomycin in two-dimensional and three-dimensional ovarian cancer cell cultures (PMID 32366058), development of a targeted delivery system based on actinomycin class drugs and recombinant alpha-fetoprotein (PMID 28510139), and computational models that include dactinomycin among the agents used to train drug response or natural product classification algorithms (PMID 35348595, PMID 40466240).

Questions better answered by a prescribing clinician

• Whether a specific diagnosis falls within a labelled indication for dactinomycin.
• Which combination regimen or protocol applies to a given stage and risk group.
• How monitoring for liver, blood count and infusion site effects is handled.
• How dactinomycin interacts with surgery, radiation or other systemic agents in a treatment plan.
• What alternatives exist, including the surgical options studied in gestational trophoblastic neoplasia (PMID 29887485).

Dactinomycin is administered in supervised clinical settings by teams experienced in cytotoxic chemotherapy. Every individual question about whether, when or how it might be used belongs with the prescribing clinician who has access to the full clinical record.

References

• Cytotoxic Antibiotics (LiverTox reference chapter, 2012)
• Wilms' tumor management (Current Opinion in Urology, 2005)
• Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial (Frontiers of Medicine, 2022)
• M-EA and EMA-CO regimens as first-line treatment of high-risk gestational trophoblastic neoplasia (International Journal of Cancer, 2021)
• Gestational trophoblastic disease (Journal of Obstetrics and Gynaecology Canada, 2002)
• First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive (Gynecologic Oncology, 2018)
• Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML (Leukemia, 2021)
• Rhabdomyosarcoma xenotransplants in zebrafish embryos (Pediatric Blood & Cancer, 2023)
• Synergy between Photodynamic Therapy and Dactinomycin Chemotherapy in 2D and 3D Ovarian Cancer Cell Cultures (International Journal of Molecular Sciences, 2020)
• Development of target delivery system based on actinomycin class drugs and recombinant alpha-fetoprotein (Doklady Biochemistry and Biophysics, 2017)
• DeepTTA: a transformer-based model for predicting cancer drug response (Briefings in Bioinformatics, 2022)
• DFT_ANPD: A dual-feature two-sided attention network for anticancer natural products detection (Computers in Biology and Medicine, 2025)